Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case

Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case

BackgroundRearranged during transfection (RET) fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential. Selpercatinib, a highly selective RET inhibitor, has demonstrated efficacy in various solid tumors harboring RET alterations. Here,...

Full description

Saved in:
Bibliographic Details
Main Authors: Raffaella Pagliaro, Paola Maria Medusa, Fabiana Vitiello, Luigi Aronne, Susan F. M. Campbell, Fabio Perrotta, Andrea Bianco
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
lung adenocarcinoma
RET fusion
selpercatinib
targeted therapy
precision medicine
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1500449/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items